Randomized trial demonstrates improved drug response prediction in hepatic malignancies, highlighting personalized therapy's potential.
Key Points
This study aims to establish a platform using patient-derived organoids (PDOs) to predict drug responsiveness in hepatic malignancies.
PDOs were created from fresh tumor tissues of 29 patients with hepatic malignancies, achieving a 79.31% success rate.
Drug sensitivity testing was conducted with standard-of-care therapeutics, and model stability was confirmed through serial passaging and cryopreservation.
Clinical correlation was assessed by prospectively comparing PDO-predicted sensitivity with actual treatment responses in 16 patients.
Patients receiving PDO-predicted sensitive agents had an objective response rate (ORR) of 36.36% (95% CI: 10.93–69.21).
Disease control rate (DCR) for patients matched with sensitive therapies was 90.91% (95% CI: 58.72–99.77), whereas those with resistant therapies had 0% ORR and 20% DCR.
PDOs demonstrated high morphological consistency and drug sensitivity reproducibility across passaging and preservation.